Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44393   clinical trials with a EudraCT protocol, of which   7405   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
    Select Country:
    		 Select Age Range:
    Select Trial Status:
    		 Select Trial Phase:
    Select Gender:
    Select Date Range:
    to
    Select Rare Disease:
    IMP with orphan designation in the indication
    Orphan Designation Number:
    Results Status:
    Clear advanced search filters
     
    2,078 result(s) found. Displaying page 11 of 104.
    «« First « Previous 7  8  9  10  11  12  13  14  15  Next» Last»»
    EudraCT Number: 2015-004293-15 Sponsor Protocol Number: UCART19_02(CL1-68587-001) Start Date*: 2016-05-24
    Sponsor Name:Institut de Recherches Internationales Servier (I.R.I.S)
    Full Title: A phase 1, open label, non-comparative, study to evaluate the safety and the ability of UCART19 to induce molecular remission in paediatric patients with relapsed /refractory B-cell acute lymphobla...
    Medical condition: Paediatric relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10060390 Leukaemia lymphoblastic acute LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) FR (Completed) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-001255-31 Sponsor Protocol Number: B7841003 Start Date*: 2018-03-28
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: A MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE LONG-TERM SAFETY, TOLERABILITY AND EFFICACY OF SUBCUTANEOUS PF-06741086 IN SUBJECTS WITH SEVERE HEMOPHILIA
    Medical condition: Severe Hemophilia A or B, with or without inhibitors to Factor VIII (FVIII) or Factor IX (FIX).
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10053751 Hemophilia A with anti factor VIII LLT
    20.1 100000004850 10053754 Hemophilia B without inhibitors LLT
    20.0 100000004850 10053753 Hemophilia A without inhibitors LLT
    20.0 100000004850 10053752 Hemophilia B with anti factor IX LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male
    Trial protocol: PL (Completed) ES (Prematurely Ended) BG (Prematurely Ended) HR (Completed)
    Trial results: View results
    EudraCT Number: 2015-002610-76 Sponsor Protocol Number: 39039039CHD3001/BAY59-7939-18226 Start Date*: 2016-09-21
    Sponsor Name:Janssen-Cilag International N.V
    Full Title: A Prospective, Open-Label, Active-Controlled Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Efficacy of Rivaroxaban for Thromboprophylaxis in Pediatric Subjects 2 to 8 Years ...
    Medical condition: thromboprophylaxis
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004850 10040729 Single ventricle LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed) FR (Completed) ES (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2012-001309-26 Sponsor Protocol Number: CSL689_2001 Start Date*: 2015-11-09
    Sponsor Name:CSL Behring GmbH
    Full Title: A multicenter, open-label, multiple-dose, dose escalation study to investigate the pharmacokinetics, efficacy, and safety of rVIIa-FP (CSL689) in subjects with hemophilia (A or B) and inhibitors.
    Medical condition: Hemophilia A with inhibitors, Hemophilia B with inhibitors
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10053751 Hemophilia A with anti factor VIII LLT
    20.0 100000004850 10053752 Hemophilia B with anti factor IX LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male
    Trial protocol: DE (Completed) GB (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-000596-34 Sponsor Protocol Number: WX17798 Start Date*: 2005-05-19
    Sponsor Name:F.Hoffmann-La Roche Ltd.
    Full Title: A prospective, randomized, double-blind, placebo controlled, parallel group, multicenter, 36-weeks trial to assess the efficacy and safety of adjunct mycophenolate mofetil (MMF) to maintain or impr...
    Medical condition: Myasthenia gravis
    Disease: Version SOC Term Classification Code Term Level
    7.1 10028417 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2005-000343-28 Sponsor Protocol Number: WX18411 Start Date*: 2005-12-19
    Sponsor Name:Aspreva Pharmaceuticals Corporation
    Full Title: An optional continuation of double-blind treatment for subjects who have achieved good symptom control with stable prednisone dosing and who have completed Protocol WX17798 (A prospective, randomiz...
    Medical condition: Myasthenia Gravis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10028417 Myasthenia gravis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-004058-20 Sponsor Protocol Number: SPD422-203 Start Date*: 2006-07-06
    Sponsor Name:Shire Pharmaceutical Development Limited
    Full Title: A phase II, open-label, multicentre, pharmacokinetic, pharmacodynamic and safety study of anagrelide hydrochloride in young (18-50 years) and elderly (≥ 65 years) patients with essential thrombocyt...
    Medical condition: Xagrid is an antineoplasic indicated for the reduction of elevated platelet counts in at risk essential thrombocythaemia patients who are intolerant to their current therapy or whose elevated plate...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) ES (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2011-001354-29 Sponsor Protocol Number: I10E-0719 Start Date*: 2011-10-12
    Sponsor Name:LFB BIOTECHNOLOGIES
    Full Title: An open-label, multicentre efficacy and safety study of I10E in patients with primary Immune ThrombocytoPenia (ITP)
    Medical condition: ITP diagnosis being defined by ASH-2011 and BCSH 2010 criteria adopting the new consensus terminology proposed by an international working group (Rodeghiero et al, 2009)
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004851 10023095 ITP LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) IT (Completed) ES (Completed)
    Trial results: Removed from public view
    EudraCT Number: 2013-000232-10 Sponsor Protocol Number: C25007 Start Date*: 2013-10-02
    Sponsor Name:Millennium Pharmaceuticals, Inc
    Full Title: A Single-arm Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin Lymphoma Who Are Not Suitable for Stem Cell Transplantation or Multiagent Chemotherapy
    Medical condition: Relapsed or Refractory Hodgkin Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    18.0 10005329 - Blood and lymphatic system disorders 10025319 Lymphomas Hodgkin's disease HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) ES (Completed) DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2006-002517-12 Sponsor Protocol Number: CC-5013-MM-018 Start Date*: 2006-06-30
    Sponsor Name:Celgene International Sàrl
    Full Title: A multicenter, single-arm, open-label safety study of lenalidomide plus dexamethasone in previously treated subjects with Multiple Myeloma.
    Medical condition: Previously treated subjects with Multiple Myeloma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) IE (Completed) GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2018-004405-64 Sponsor Protocol Number: MT-2-03 Start Date*: 2019-03-07
    Sponsor Name:Minoryx Therapeutics BE, SA
    Full Title: A Double-Blind, Placebo-Controlled Study on the Effects of MIN-102 on Biochemical, Imaging, Neurophysiological, and Clinical Markers in Patients with Friedreich’s Ataxia
    Medical condition: Friedreich’s Ataxia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10017374 Friedreich's ataxia PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: BE (Completed) FR (Completed) DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2008-003572-21 Sponsor Protocol Number: A7331009 Start Date*: 2009-11-19
    Sponsor Name:Pfizer Ltd,Ramsgate Road,Sandwich,Kent CT13 9NJ
    Full Title: A PHASE 2A, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY INVESTIGATING THE DOSE-RESPONSE OF PF-00489791 ON ACUTE HEMODYNAMICS IN SUBJECTS WITH IDIOPATHIC AND FAMILIAL PULMONAR...
    Medical condition: Pulmonary arterial hypertension.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064911 Pulmonary arterial hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) BE (Completed) DE (Prematurely Ended) ES (Completed)
    Trial results: View results
    EudraCT Number: 2009-012857-39 Sponsor Protocol Number: A4021032 Start Date*: 2009-11-16
    Sponsor Name:PFIZER, S.A.
    Full Title: “ESTUDIO DE FASE 2, ALEATORIZADO Y ABIERTO DE FIGITUMUMAB (CP-751,871) MÁS CISPLATINO (O CARBOPLATINO) Y ETOPOSIDO, FRENTE A CISPLATINO (O CARBOPLATINO) Y ETOPOSIDO SOLOS, COMO TRATAMIENTO DE PRIME...
    Medical condition: Pacientes con cáncer de pulmón microcítico en estadio extendido que no hayan recibido quimioterapia previa para su enfermedad.
    Disease: Version SOC Term Classification Code Term Level
    12.0 10041068 Small cell lung cancer extensive stage LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) HU (Completed) BG (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-001955-54 Sponsor Protocol Number: BMN-051-302 Start Date*: 2015-12-08
    Sponsor Name:BioMarin Nederland BV
    Full Title: An open-label extension study of the long-term safety, tolerability and efficacy of drisapersen in subjects with Duchenne Muscular Dystrophy.
    Medical condition: Duchenne Muscular Dystrophy (DMD)
    Disease: Version SOC Term Classification Code Term Level
    18.0 10010331 - Congenital, familial and genetic disorders 10013801 Duchenne muscular dystrophy PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male
    Trial protocol: NL (Prematurely Ended) DE (Completed) BE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2015-002406-37 Sponsor Protocol Number: 170 Start Date*: 2016-02-24
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck Co., Inc
    Full Title: A Phase 2 Study of Pembrolizumab (MK 3475) in Subjects with Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) or Relapsed or Refractory Richter Syndrome (rrRS)
    Medical condition: relapsed or refractory Primary Mediastinal Large B-Cell Lymphoma or Relapsed or Refractory Richter Syndrome (rrRS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036710 Primary mediastinal large B-cell lymphoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10058728 Richter's syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) PL (Completed) ES (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2012-001995-12 Sponsor Protocol Number: I10E-0901 Start Date*: 2015-05-19
    Sponsor Name:LFB BIOTECHNOLOGIES
    Full Title: A European, randomised, double-blind, active comparator-controlled, cross-over, efficacy and safety study of a new 10% ready-to-use liquid human intravenous immunoglobulin (I10E) versus Kiovig® in ...
    Medical condition: Multifocal motor neuropathy (MMN)
    Disease: Version SOC Term Classification Code Term Level
    15.1 10029205 - Nervous system disorders 10065579 Multifocal motor neuropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) GB (Completed) ES (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2015-005541-30 Sponsor Protocol Number: APD003 Start Date*: 2016-08-23
    Sponsor Name:UCB BioPharma SPRL
    Full Title: AN OPEN-LABEL, EXPLORATORY, MULTICENTER, EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY, TOLERABILITY, PHARMACOKINETICS AND EFFICACY OF UCB5857 IN SUBJECTS WITH ACTIVATED PHOSPHOINOSITIDE 3 KINAS...
    Medical condition: Activated PI3K delta Syndrome (APDS)
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) ES (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2013-003714-40 Sponsor Protocol Number: HCQinpediatricILD Start Date*: 2015-01-20
    Sponsor Name:Klinikum der Ludwig-Maximilian-Universität München
    Full Title: Hydroxychloroquine in pediatric ILD START randomized controlled in parallel-group, then switch placebo to active drug, and STOP randomized controlled in parallel-group to evaluate the efficacy and...
    Medical condition: interstitial lung disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10022611 Interstitial lung disease PT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Ongoing) GB (GB - no longer in EU/EEA) AT (Prematurely Ended) ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-005115-13 Sponsor Protocol Number: ISIS420915-CS4 Start Date*: 2018-04-25
    Sponsor Name:Ionis Pharmaceuticals, Inc.
    Full Title: A Non-Interventional Study to Monitor the Survival Status of Patients that Discontinued from ISIS 420915-CS2 or ISIS 420915-CS3
    Medical condition: Familial Amyloid Polyneuropathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10057949 Familial amyloid polyneuropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Ongoing) GB (Completed) PT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-004113-85 Sponsor Protocol Number: PA101-SM-02 Start Date*: 2015-04-16
    Sponsor Name:Patara Pharma, LLC
    Full Title: Randomized, Double-blind, Placebo-controlled, Crossover Design, Efficacy and Safety Study with PA101 in Patients with Indolent Systemic Mastocytosis
    Medical condition: Indolent Systemic Mastocytosis
    Disease: Version SOC Term Classification Code Term Level
    18.0 10005329 - Blood and lymphatic system disorders 10042949 Systemic mastocytosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 7  8  9  10  11  12  13  14  15  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Apr 03 19:51:45 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA